Chemistry:Pamapimod
From HandWiki
Pamapimod is an investigational drug which is being evaluated for the treatment of autoimmune diseases. It is a p38 mitogen-activated protein kinase inhibitor.[1] It has been evaluated in a phase 2 clinical trial for the treatment of rheumatoid arthritis, but was found not to be effective.[2][3] It has subsequently been investigated as a possible treatment for osteoarthritis.[4][5]
See also
- NJK14047
- PH-797804
References
- ↑ "Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity". The Journal of Pharmacology and Experimental Therapeutics 327 (3): 610–9. December 2008. doi:10.1124/jpet.108.139006. PMID 18776065.
- ↑ "Kinase inhibitors: a new approach to rheumatoid arthritis treatment". Current Opinion in Rheumatology 22 (3): 330–5. May 2010. doi:10.1097/BOR.0b013e3283378e6f. PMID 20164774.
- ↑ "Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis". Arthritis and Rheumatism 60 (2): 335–344. February 2009. doi:10.1002/art.24266. PMID 19180516.
- ↑ "The Novel p38 Inhibitor, Pamapimod, Inhibits Osteoclastogenesis and Counteracts Estrogen-Dependent Bone Loss in Mice". Journal of Bone and Mineral Research 34 (5): 911–922. May 2019. doi:10.1002/jbmr.3655. PMID 30615802.
- ↑ "Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy". Panminerva Medica 66 (4): 365–371. December 2020. doi:10.23736/S0031-0808.20.04170-1. PMID 33263251.
 |  |
